Vaxcell-Bio Therapeutics (XKRX:323990) Total Stockholders Equity : ₩71,572 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Vaxcell-Bio Therapeutics Total Stockholders Equity?

Vaxcell-Bio Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2025 was ₩71,572 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Vaxcell-Bio Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 was ₩3,116.58. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Vaxcell-Bio Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.00.

Vaxcell-Bio Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Vaxcell-Bio Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcell-Bio Therapeutics Total Stockholders Equity Chart

Vaxcell-Bio Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

34,667.42

30,080.38

23,327.27

83,493.27

71,994.12

Vaxcell-Bio Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															81,143.31	78,274.65	75,054.24	71,994.12	71,572.18

Vaxcell-Bio Therapeutics (XKRX:323990) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Vaxcell-Bio Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(71572.181	-	0)	/	22.965
	=	3,116.58

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Vaxcell-Bio Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	71572.181
	=	0.00

Vaxcell-Bio Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Vaxcell-Bio Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxcell-Bio Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcell-Bio Therapeutics (XKRX:323990) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

12-55, Sandan-gil, Hwasun-eup, Hwasun-gun, Jeollanam-do, Yeosu, KOR, 58141

Website

http://www.vaxcell-bio.com

Vaxcell-Bio Therapeutics is a bio-technology company engaged in the development of Cell-based and Protein-based Immunotherapeutics for the treatment of cancer.

Vaxcell-Bio Therapeutics Headlines

No Headlines